| 11.95 -0.04 (-0.33%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.3 | 1-year : | 16.71 |
| Resists | First : | 12.25 | Second : | 14.3 |
| Pivot price | 11.98  |
|||
| Supports | First : | 11.34 | Second : | 10.78 |
| MAs | MA(5) : | 11.95  |
MA(20) : | 11.96 |
| MA(100) : | 11.86 | MA(250) : | 11.48 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.4 |
D(3) : | 59.7 |
| RSI | RSI(14): 53.2 | |||
| 52-week | High : | 14.46 | Low : | 9.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCS ] has closed above bottom band by 27.6%. Bollinger Bands are 79.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.05 - 12.14 | 12.14 - 12.2 |
| Low: | 11.62 - 11.71 | 11.71 - 11.78 |
| Close: | 11.83 - 11.97 | 11.97 - 12.08 |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Mon, 09 Sep 2024
Equities Analysts Offer Predictions for Oculis Holding AG's Q3 2024 Earnings (NASDAQ:OCS) - MarketBeat
Sun, 01 Sep 2024
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - MarketBeat
Thu, 29 Aug 2024
Oculis to Present at Upcoming September Investor Conferences - GlobeNewswire
Wed, 28 Aug 2024
Oculis Reports 2024 Second Quarter Financial Results - Vision Monday
Tue, 27 Aug 2024
Oculis Holding Shows Strong Asset and Equity Growth - TipRanks
Tue, 27 Aug 2024
Oculis Reports Q2 Financial Results and Provides Recent Company Update - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 3.955e+007 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.284e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 177.5 % |
| Return on Equity (ttm) | -28.8 % |
| Qtrly Rev. Growth | 871000 % |
| Gross Profit (p.s.) | -22.23 |
| Sales Per Share | -645.78 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.39 |
| Dividend | 0 |
| Forward Dividend | 18910 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|